Showing results (81-90 of 108) with videos related to

Sort By:
Pageof 11
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 1, 1994
European-Canadian randomized trial of paclitaxel in relapsed ovarian cancer: high-dose versus low-dose and long versus short infusionE A Eisenhauer, W W ten Bokkel Huinink, K D Swenerton, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|September 25, 2012
A randomized phase II study evaluating the combination of carboplatin-based chemotherapy with pertuzumab versus carboplatin-based therapy alone in patients with relapsed, platinum-sensitive ovarian cancerS B Kaye, C J Poole, A Dańska-Bidzińska, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|September 26, 2017
Selecting patients for resection after primary chemotherapy for non-metastatic pancreatic adenocarcinomaM Reni, S Zanon, G Balzano, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|January 22, 2000
Stage-modified international prognostic index effectively predicts clinical outcome of localized primary gastric diffuse large B-cell lymphoma. International Extranodal Lymphoma Study Group (IELSG)S Cortelazzo, A Rossi, F Roggero, et al.
Seminars in Oncology|November 28, 1997
Pilot study of primary chemotherapy with doxorubicin plus paclitaxel in women with locally advanced or operable breast cancerA Moliterni, E Tarenzi, G Capri, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|November 11, 2009
Phase Ib study of weekly mammalian target of rapamycin inhibitor ridaforolimus (AP23573; MK-8669) with weekly paclitaxelC Sessa, D Tosi, L Viganò, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|October 19, 2000
Clinical and pharmacological phase I study with accelerated titration design of a daily times five schedule of BBR3464, a novel cationic triplatinum complexC Sessa, G Capri, L Gianni, et al.
European Journal of Cancer (Oxford, England : 1990)|December 31, 2008
Phase I clinical and pharmacokinetic study of trabectedin and doxorubicin in advanced soft tissue sarcoma and breast cancerC Sessa, A Perotti, C Noberasco, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|February 15, 2008
p27 and Skp2 immunoreactivity and its clinical significance with endocrine and chemo-endocrine treatments in node-negative early breast cancerA Ravaioli, F Monti, M M Regan, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 1, 2002
Phase I safety, pharmacokinetic, and pharmacodynamic trial of ZD1839, a selective oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with five selected solid tumor typesJ Baselga, D Rischin, M Ranson, et al.
Pageof 11